Academic Literature

Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy

Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
Originally published on 05/13/2021 in The American Journal of Managed Care

Specialty pharmacy drugs are the greatest drivers of prescription drug spending in the US. They account for 46.5% of spending on pharmaceuticals despite comprising only 1.9% of prescriptions dispensed.

Because of this, specialty drugs are attractive targets for more active management

The study used three focus groups with four total business objectives identified. The business objectives centered around spending levels, spending variability, access to new treatments, and evidence generation for new treatments. Factors that influenced their ability to act on the strategies included regional and national scale, the strength of provider network relationships, disease managements capabilities, business and data silos, and potential legislative actions to limit utilization management. 

In conclusion, the researchers suggested that plans’ preferences for different forms of specialty pharmacy management may not be aligned with policy objectives, in particular those that advance innovation. Policymakers should consider both limiters and incentives in the market and non-market environments in which plans operate. This includes the need to mitigate spending variability and generate evidence to guide coverage decisions.

Access the full article here.

Key Takeaways

Policy makers and health plans must work to make new treatments available while balancing cost concerns. While there are many approaches to achieving this goal, not all are equally effective.

Due to spending variability, budget constraints, insufficient clinical evidence, competitive pressures, and data and human resource constraints, health plans experience pressure to pursue long-term financing and outcomes-based contracting approaches.

Value-based management of specialty prescription drugs is superior to long-term financing and outcomes-based contracts, but will require policy initiatives that incentivize value-based pricing and insurance design.

Share

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Value-Based Management of Specialty Drugs: Practical Considerations and Implications for…
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
AJMC 05/13/2021
Pharmaceutical Products and Their Value: Lessons Learned and the Path…
Value-based pricing has emerged as an alternative to prices determined by what the market will bear. But which agreements are truly "value-based"?
Value in Health 03/29/2021
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Value-Based Pricing for Drugs: Theme and Variations
A taxonomy of the features that make a payment model truly value-based.
JAMA Viewpoint 05/02/2018
Outcomes-Based Drug Contracts Do Not Move Us Closer to Value
What steps are needed to make outcomes-based contracting a value-based approach?
Morning Consult 06/21/2017
The Drugs at the Heart of Our Pricing Crisis
The US drug pricing system is broken, but not irreparable. For large-molecule biologic drugs, enter: Production Plus Profit Pricing (P-quad, pronounced like Ahab's seagoing vessel).
NYTimes 03/15/2021
Biosimilars: Market Changes do not equal policy success
Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.
Drug Pricing Lab 03/15/2021
Bottom-Up Pricing Estimate for P-quad
How much would biologic drugs cost under P-quad pricing? Two approaches to estimating fully loaded costs plus a profit (10% and 20% examined) suggest net discounts from current prices would be at least 65% to 75%
Drug Pricing Lab 03/12/2021
Modeling P-quad
The Drug Pricing Lab engaged Milliman to conduct an independent analysis of the Production Plus Profit Pricing (P-quad) policy proposal. The Milliman analysis estimates the projected spending on U.S. biologic and biosimilar drugs under a referent scenario where there is no biosimilar entry or competition, the existing ‘status quo’ scenario under the current biosimilar environment, and the Drug Pricing Lab’s P-quad policy proposal. 

This report was commissioned by Drug Pricing Lab.
Milliman 03/12/2021
Ethics of Clinical Trials to Evaluate Biosimilars
Biosimilars require extensive, expensive, and time-consuming human testing prior to market entry, a process vastly different than generics. So why are we still doing them?
MedRx IV 03/09/2021
COVID-19 Reduced Average Life Expectancy of Americans by Five Days,…
The CDC made a mistake.
STAT 02/25/2021
Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US…
Medical students' education covers topics spanning health, disease, and treatment, but what about drug pricing and their role as prescribers?
Medical Science Educator 01/13/2021
Newsletter

Stay up to date on our work and news